Geron Corporation’s $375 Million Funding

Fenwick & West represented Royalty Pharma in the transaction.Geron Corporation (Nasdaq: GERN) announced that Royalty Pharma (Nasdaq: PRRX), a buyer of biopharmaceutical royalties and funder of…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here

Author: Leila Ahmed

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here